Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2− early breast cancer: a discrete choice survey study
This study demonstrated that patients prefer adjuvant treatment with higher efficacy and lower risk of adverse events. These data will aid shared decision-making when discussing the addition of CDK4/6is to adjuvant ET for eligible patients with HR+/HER2- EBC.
Authors
- Remi Bellefleur (ORCID: https://orcid.org/0000-0001-9540-9519)
- Wendi Qu (ORCID: https://orcid.org/0000-0002-2326-9243)
- Mary Lou Smith (ORCID: https://orcid.org/0000-0002-1937-1026)
- Robert Morlock (ORCID: https://orcid.org/0000-0002-8723-2562)
- Erica L. Mayer (ORCID: https://orcid.org/0000-0001-5430-8957)
- Nisha C. Hazra (ORCID: https://orcid.org/0000-0002-1424-6525)
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Liz Santarsiero
- Yan Meng (ORCID: https://orcid.org/0000-0002-0614-8968)
- Vaidyanathan Ganapathy
- Annie Guérin
Institutions
- Dana-Farber Cancer Institute (US)
- Novartis (United States) (US)
- Dana-Farber/Harvard Cancer Center (US)
- Institute of Group Analysis (GB)
- Research Advocacy Network (US)
- Smilow Cancer Hospital (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1007/s10549-025-07627-4
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Novartis Pharmaceuticals Corporation